Lama H Nazer1, Asma Kharabsheh1, Dalia Rimawi2, Sawsan Mubarak3, Feras Hawari4. 1. 1 Department of Pharmacy, King Hussein Cancer Center , Amman, Jordan . 2. 2 Biostatistics Unit, Research Office, King Hussein Cancer Center , Amman, Jordan . 3. 3 Department of Infection Control, King Hussein Cancer Center , Amman, Jordan . 4. 4 Section of Pulmonary and Critical Care, Department of Medicine, King Hussein Cancer Center , Amman, Jordan .
Abstract
AIM: To describe the characteristics and outcomes of Acinetobacter baumannii (AB) infections in critically ill cancer patients and to evaluate the impact of AB on mortality and length of stay (LOS). RESULTS: In a 4-year case-control study of critically ill cancer patients, we identified 161 patients with AB infections and 232 matched patients who were treated in the intensive care unit (ICU) during the same time period, but had no AB cultures. The case and control groups were matched for APACHE II, age, gender, type of malignancy, and mechanical ventilation. Most AB isolates were carbapenem-resistant (n=142, 88.2%). The majority of positive cultures were collected from the respiratory tract (58%) and blood (21.8%). The median ICU LOS and mortality rate for patients with AB infections were higher than those for the control group (12 days [IQR 6-23] vs. 3 days [IQR 1-7], p<0.0001 and 73.3% vs. 61.5%, p=0.015, respectively). AB infection was independently associated with ICU LOS and mortality: OR 1.108 (95% CI, 1.077-1.139), OR 1.658 (95% CI, 1.017-2.703), respectively. CONCLUSION: AB infections in critically ill cancer patients were independently associated with increased mortality and increased ICU LOS. Measures to improve the outcomes of critically ill cancer patients infected with AB are necessary.
AIM: To describe the characteristics and outcomes of Acinetobacter baumannii (AB) infections in critically ill cancerpatients and to evaluate the impact of AB on mortality and length of stay (LOS). RESULTS: In a 4-year case-control study of critically ill cancerpatients, we identified 161 patients with AB infections and 232 matched patients who were treated in the intensive care unit (ICU) during the same time period, but had no AB cultures. The case and control groups were matched for APACHE II, age, gender, type of malignancy, and mechanical ventilation. Most AB isolates were carbapenem-resistant (n=142, 88.2%). The majority of positive cultures were collected from the respiratory tract (58%) and blood (21.8%). The median ICU LOS and mortality rate for patients with AB infections were higher than those for the control group (12 days [IQR 6-23] vs. 3 days [IQR 1-7], p<0.0001 and 73.3% vs. 61.5%, p=0.015, respectively). AB infection was independently associated with ICU LOS and mortality: OR 1.108 (95% CI, 1.077-1.139), OR 1.658 (95% CI, 1.017-2.703), respectively. CONCLUSION:AB infections in critically ill cancerpatients were independently associated with increased mortality and increased ICU LOS. Measures to improve the outcomes of critically ill cancerpatients infected with AB are necessary.
Authors: X Wang; L Zhang; A Sun; X Yang; W Sang; Y Jiang; J Cheng; J Wang; M Zhou; B Chen; J Ouyang Journal: Eur J Clin Microbiol Infect Dis Date: 2017-01-18 Impact factor: 3.267
Authors: Mohammad Al-Tamimi; Hadeel Albalawi; Mohamd Alkhawaldeh; Abdullah Alazzam; Hassan Ramadan; Majd Altalalwah; Ahmad Alma'aitah; Dua'a Al Balawi; Sharif Shalabi; Jumana Abu-Raideh; Ashraf I Khasawneh; Farah Alhaj; Kamal Hijawi Journal: Microorganisms Date: 2022-04-20